Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xofigo in symptomatic hormone refractory prostate cancer with bone metastases
NCT00699751Phase 3Completed
- Sponsor
- Bayer
- Start
- Jun 2008
- Primary completion
- Jul 2011
- Countries
- 19
01
Overview
A Phase 3 trial of radium-223 dichloride in prostate cancer (PCa), bone metastases, sponsored by Bayer. Started Jun 2008; status: completed.
02
Drugs
radium-223 dichloride
03
Conditions
prostate cancer (PCa)bone metastases
Beyond the preview
Go deeper on NCT00699751.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00699751.